Department of Respiratory Medicine, Alfred Hospital, Melbourne, Australia; Department of Medicine, Monash University, Melbourne, Australia.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
J Thorac Oncol. 2021 May;16(5):784-797. doi: 10.1016/j.jtho.2021.01.1622. Epub 2021 Feb 12.
Patients with NSCLC may be treated with curative intent, yet they remain at high risk of both disease recurrence and second primary lung cancer (SPLC) and increased risk of early death. Guidelines provide recommendations for follow-up, but there is little consensus, and review of available evidence is necessary. The use of a systematic follow-up strategy for the detection of disease recurrence or SPLC after curative-intent treatment of NSCLC may increase the proportion of patients available for retreatment and increase the survival of patients with surveillance detection.
We performed a systematic review and meta-analysis of prospective studies on follow-up of NSCLC after curative-intent treatment to answer the following three questions: What is the effect of follow-up on detection of recurrence or SPLC? What is the effect of surveillance detection on curative-intent retreatment? What is the survival impact?
Recurrence or SPLC was observed in 17.8% to 71% of patients. Scheduled imaging-detected recurrence in 60% to 100% of cases, yet neither computed tomography-based (OR = 2.31, 95% confidence interval [CI]: 0.27-19.49, p = 0.44) nor positron emission tomography-computed tomography-based follow-up (OR = 1.431, 95% CI: 0.92-2.22, p = 0.12) was statistically superior to standard follow-up strategies. Detection of disease recurrence/SPLC significantly increased the odds of curative-intent retreatment (OR = 4.31; 95% CI: 2.10-8.84, p < 0.0001). Curative-intent retreatment prolonged survival in reported studies.
The early detection of disease recurrence/SPLC may increase the likelihood of curative-intent retreatment and prolong survival. There is a clear need for prospective randomized controlled studies of follow-up to confirm effectiveness of available follow-up modalities.
接受以治愈为目的治疗的 NSCLC 患者仍存在疾病复发和第二原发性肺癌(SPLC)的高风险,且死亡风险增加。指南提供了随访建议,但目前尚缺乏共识,有必要对现有证据进行审查。在以治愈为目的治疗 NSCLC 后,采用系统的随访策略检测疾病复发或 SPLC,可能会增加可接受再次治疗的患者比例,并提高经监测检测发现的患者的生存率。
我们对以治愈为目的治疗 NSCLC 后进行随访的前瞻性研究进行了系统回顾和荟萃分析,以回答以下三个问题:随访对检测复发或 SPLC 的效果如何?监测检测对以治愈为目的的再次治疗的效果如何?对生存的影响如何?
17.8%至 71%的患者出现复发或 SPLC。在 60%至 100%的病例中,通过计划的影像学检测到复发,但基于计算机断层扫描(OR=2.31,95%置信区间[CI]:0.27-19.49,p=0.44)或正电子发射断层扫描-计算机断层扫描(OR=1.431,95%CI:0.92-2.22,p=0.12)的随访均未显示出统计学优势。检测到疾病复发/SPLC 显著增加了以治愈为目的再次治疗的可能性(OR=4.31;95%CI:2.10-8.84,p<0.0001)。报道的研究中,以治愈为目的的再次治疗延长了患者的生存时间。
早期检测疾病复发/SPLC 可能会增加以治愈为目的再次治疗的可能性并延长生存时间。需要进行前瞻性随机对照研究,以证实现有随访方式的有效性。